ab801
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 16, 2023 (NCT06004921)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase receptor UFOINHIBITOR
AXL inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06120075 | Phase 1 | Dec 1, 2023 | Arcus Biosciences, Inc. |
| NCT06004921 | Phase 1 | Oct 16, 2023 | Arcus Biosciences, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arcus Biosciences, Inc. | For profit | 2 | 2 | 1 | 2023 |
1 organizations
Page 1 / 1